Biotricity Expands Reach into Pulmonary and Neurology Markets through New Partnerships

Biotricity Inc. (NASDAQ:BTCY), a pioneer in Technology-as-a-Service for healthcare, revealed strategic alliances with leaders in neurology and sleep apnea diagnostics. Responding to the overlapping issues of sleep and neurological disorders with cardiac risks, these collaborations aim to provide comprehensive, holistic screenings. This initiative underlines Biotricity's dedication to integrated healthcare solutions for multifaceted patient needs.

In the U.S., over 39 million people suffer from obstructive sleep apnea (OSA), with a significant overlap with cardiovascular diseases (CVD), intensifying the need for comprehensive healthcare access. The frequency of cardiac arrhythmias in these patients underscores the importance of these new healthcare partnerships.

Similarly affected are the vast numbers coping with neurological disorders, leading to dramatic mortality rates and associations with CVD, including potential links to conditions like dementia and Alzheimer's disease. By extending into home-based diagnostics, Biotricity fortifies its capabilities to address these complex comorbidities through early detection and intervention.

Dr. Waqaas Al-Siddiq, CEO of Biotricity, expressed enthusiasm about enriching their service offerings to previously underserved patients. This strategic direction not only enhances care quality but also potentially reduces risks like strokes and heart attacks significantly through early medical intervention.